For the Inventor, By the Inventor

Enter assignee name

Cantargia Ab

Calculating rank

USPTO Granted Patents = 18

EPO Patents = 8

Forward Citations = 88

Loading Chart...

Loading Chart...

17 inventors (with patents filed for the assignee):

Thoas Fioretos (14 out of 14 patents)

Marcus Järås (14 out of 14 patents)

Kjell Sjöström (10 out of 15 patents)

4. Karin Von Wachenfeldt (10 out of 16 patents)

5. Cecilia Ann-Christin Malmborg Hager (7 out of 10 patents)

6. Helena Ågerstam (7 out of 7 patents)

7. Agneta Svedberg (7 out of 9 patents)

8. David Liberg (3 out of 8 patents)

9. Camilla Rydberg Millrud (2 out of 2 patents)

10. Gabriel Svensson Birkedal (2 out of 2 patents)

11. Sara Rattik (2 out of 2 patents)

12. Ying Ping Jiang (1 out of 1 patent)

13. Leonard G Presta (1 out of 1 patent)

14. Göran Forsberg (1 out of 7 patents)

15. Caitríona Grönberg (1 out of 1 patent)

18 patents: Sort by Forward Citations

1. 12398213 - Methods of treating IL1RAP associated cancers with anti human interleukin-1 receptor accessory protein (IL1 RAP) antibodies (2025-08-26),

2. 12209131 - Anti-IL1RAP antibody compositions (2025-01-28),

3. 12043666 - Anti-IL1RAP antibody (2024-07-23),

4. 11773174 - Anti-IL1RAP antibodies and their use for treating humans (2023-10-03),

5. 11479610 - Anti-IL1RAP antibody (2022-10-25),

6. 11359025 - Anti-IL1-RAP antibodies (2022-06-14),

7. 11236172 - Methods of producing an IL-1 RAP antibodies (2022-02-01),

8. 10995144 - Methods of detecting a solid tumor with anti-IL1RAP antibodies (2021-05-04),

9. 10878703 - Method of treatment of leukemia with anti-IL1RAP antibodies (2020-12-29),

10. 10752692 - Anti human interleukin-1 receptor accessory protein (IL1 RAP) antibodies and uses thereof (2020-08-25),

11. 10562971 - Method of detection of IL1RAP on cells expressing the protein (2020-02-18),

12. 10287357 - Methods of treating cancer using anti human interleukin-1 receptor accessory protein (IL1 RAP) antibodies (2019-05-14),

13. 10100119 - Anti-human interleukin-1 receptor accessory protein antibody and its use for treating cancer (2018-10-16),

14. 10005842 - Method of treatment for leukemia using an anti-IL1RAP antibody (2018-06-26),

15. 10005841 - Method of treating a solid tumor with IL1RAP antibodies (2018-06-26),

Company Overview

Cantargia Ab is a biotechnology company based in Lund, Sweden, specializing in the development of innovative therapies for cancer and autoimmune diseases. The company focuses on harnessing the power of monoclonal antibodies to target specific disease mechanisms, aiming to improve treatment outcomes for patients. With a strong emphasis on research and development, Cantargia is dedicated to advancing its proprietary drug candidates through clinical trials, contributing to the evolving landscape of targeted therapies in the biopharmaceutical sector.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

18 Patents

#26 in Lund

#365 in Sweden

#34,244 in the World

Cantargia Ab

Forward Citations = 88

17 inventors:

Thoas Fioretos (14 out of 14 patents)

Marcus Järås (14 out of 14 patents)

Kjell Sjöström (10 out of 15 patents)

4. Karin Von Wachenfeldt (10 out of 16 patents)

5. Cecilia Ann-Christin Malmborg Hager (7 out of 10 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Cantargia Ab. Retrieved from https://idiyas.com/company/cantargia-ab

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…